Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors

Impact · against what's priced in

The announcement of a legal investigation by Wolf Popper LLP is not a catalyst for Ionis Pharmaceuticals, as the market has already factored in legal fallout from the eplontersen trial failure.

IONS+0.00

Already priced in

The price assumes

The ongoing legal investigations into whether management made misleading statements about the failed eplontersen trial.

The price already assumes the existence of legal investigations following the eplontersen trial failure; the initiation of a specific investigation by Wolf Popper LLP provides no new material risk.